SABS SAB Biotherapeutics, Inc. - Common Stock
$3.73
Price · May 20, 2026
52W Range
$2–$7
43% of range
Analyst Rating
BUY
14 analysts
Price Target
$10
+164% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
SABS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$3.73
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$2 – $7
SABS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
SABS
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
SABS
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
SABS
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
SABS
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
SABS
Peer Median
SABS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
14 analysts
- Strong Buy 5 35.7%
- Buy 8 57.1%
- Hold 1 7.1%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
8 analysts · 2026-05-16
Median
$8.50
Mean
$9.88
← Below all targets
$3.73
Low
$6.00
High
$15.00
Median target
$8.50
+127.6%
Mean target
$9.88
+164.5%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.06%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-0.35 | $-0.23 | -0.12% |
| Dec. 31, 2025 | $-0.35 | $-0.20 | -0.15% |
| Sept. 30, 2025 | $-0.15 | $-0.52 | 0.37% |
| June 30, 2025 | $-1.09 | $-0.81 | -0.28% |
| March 31, 2025 | $-0.56 | $-1.05 | 0.49% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| SABS | — | — | — | — | — | — |
| DMAC | $428M | — | — | — | -78.7% | — |
| ABEO | $290M | 5.2 | 147.5% | 1223.1% | 44.1% | — |
| ELDN | $114M | -2.9 | — | — | -69.4% | — |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | — |
| NVCT | $194M | -5.7 | — | — | -149.9% | — |
| MGNX | $102M | -1.4 | -0.31% | -49.9% | -87.0% | — |
| PRLD | — | -2.2 | 73.4% | -819.6% | -137.7% | — |
| ALXO | $61M | -0.6 | — | — | -225.0% | — |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.